These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34295472)

  • 21. Erratum: Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells.
    Zhang X; Peng L; Liang Z; Kou Z; Chen Y; Shi G; Li X; Liang Y; Wang F; Shi Y
    Mol Ther Nucleic Acids; 2023 Sep; 33():428-429. PubMed ID: 37575282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.
    Choi BD; Yu X; Castano AP; Bouffard AA; Schmidts A; Larson RC; Bailey SR; Boroughs AC; Frigault MJ; Leick MB; Scarfò I; Cetrulo CL; Demehri S; Nahed BV; Cahill DP; Wakimoto H; Curry WT; Carter BS; Maus MV
    Nat Biotechnol; 2019 Sep; 37(9):1049-1058. PubMed ID: 31332324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
    Choi BD; Curry WT; Carter BS; Maus MV
    Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetically engineered T cells to target EGFRvIII expressing glioblastoma.
    Bullain SS; Sahin A; Szentirmai O; Sanchez C; Lin N; Baratta E; Waterman P; Weissleder R; Mulligan RC; Carter BS
    J Neurooncol; 2009 Sep; 94(3):373-82. PubMed ID: 19387557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
    Morgan RA; Johnson LA; Davis JL; Zheng Z; Woolard KD; Reap EA; Feldman SA; Chinnasamy N; Kuan CT; Song H; Zhang W; Fine HA; Rosenberg SA
    Hum Gene Ther; 2012 Oct; 23(10):1043-53. PubMed ID: 22780919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma.
    Choi BD; O'Rourke DM; Maus MV
    J Target Ther Cancer; 2017 Aug; 6(4):22-25. PubMed ID: 29167820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
    Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
    Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogression-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells.
    Nakazawa T; Murakami T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Park YS; Motoyama Y; Tsujimura T; Wakabayashi T; Nakase H
    Anticancer Res; 2020 Jun; 40(6):3231-3237. PubMed ID: 32487617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
    Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erratum: Novel differential linear B-cell epitopes to identify Zika and dengue virus infections in patients.
    Amrun SN; Yee WX; Abu Bakar F; Lee B; Kam YW; Lum FM; Tan JJ; Lim VW; Watthanaworawit W; Ling C; Nosten F; Renia L; Leo YS; Ng LF
    Clin Transl Immunology; 2020; 9(2):e01118. PubMed ID: 32099653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.
    Ellwanger K; Reusch U; Fucek I; Knackmuss S; Weichel M; Gantke T; Molkenthin V; Zhukovsky EA; Tesar M; Treder M
    Front Oncol; 2017; 7():100. PubMed ID: 28596941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms.
    Thokala R; Binder ZA; Yin Y; Zhang L; Zhang JV; Zhang DY; Milone MC; Ming GL; Song H; O'Rourke DM
    Front Oncol; 2021; 11():664236. PubMed ID: 34568006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erratum: Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells.
    Reighard SD; Cranert SA; Rangel KM; Ali A; Gyurova IE; de la Cruz-Lynch AT; Tuazon JA; Khodoun MV; Kottyan LC; Smith DF; Brunner HI; Waggoner SN
    Cell Rep Med; 2020 Aug; 1(5):100080. PubMed ID: 33205070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erratum: Genome-wide association studies of multiple sclerosis.
    Cotsapas C; Mitrovic M
    Clin Transl Immunology; 2018; 7(8):e1038. PubMed ID: 30128152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erratum: Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.
    Bai Y; Kan S; Zhou S; Wang Y; Xu J; Cooke JP; Wen J; Deng H
    Cell Discov; 2016; 2():15052. PubMed ID: 27462841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erratum: Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.
    Bai Y; Kan S; Zhou S; Wang Y; Xu J; Cooke JP; Wen J; Deng H
    Cell Discov; 2016; 2():16032. PubMed ID: 27625791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer.
    Denholt CL; Binderup T; Stockhausen MT; Poulsen HS; Spang-Thomsen M; Hansen PR; Gillings N; Kjær A
    Nucl Med Biol; 2011 May; 38(4):509-15. PubMed ID: 21531288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.